Bear Creek Capital Presents Gain Therapeutics, Inc.-Orlando Lunch

7488 West Sand Lake Road,Orlando FL 32819

24 May, 2021

Description

Come learn more about Gain Therapeutics, Inc. (NASDAQ: GANX) and their management team. *Due to limited seating, please make sure each individual registers accordingly. You will not be permitted to attend the event without proper registration. Bear Creek Capital Presents:Lunch & Corporate PresentationGain Therapeutics, Inc. (NASDAQ:  GANX)Monday, May 24, 2021Eddie V's Prime Seafood7488 W Sand Lake RoadOrlando, FL 32819Promptly at 12:00 PMJoin Gain Therapeutics, Inc. CEO Eric Richman for this exclusive corporate presentation, followed by a Q & A session moderated by Bear Creek Capital, featuring questions taken from the audience. We hope you can join our presentation About Gain Therapeutics, Inc.LEADING THE DISCOVERY of Allosteric Binding Sites to Create New Medicines Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding, including lysosomal storage disorders. Protein misfolding is an underlying biological issue of many diseases, including lysosomal storage disorders and some neurodegenerative diseases such as Parkinson’s disease. When a protein misfolds, its 3D structure is disrupted and it can no longer function properly. While some treatments are available for these types of disorders, they have significant limitations. Gain was originally established in 2017 with the support of its founders and institutional investors such as TiVenture, 3B Future Health Fund (previously known as Helsinn Investment Fund) and VitaTech. It has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc. In the NewsGain Therapeutics, Inc. Reports First Quarter 2021 Financial ResultsGain Therapeutics Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds for the Treatment of GBA1 Parkinson’s Disease & Related α-synucleopathies at the XXVI IAPRD World Congress Gain Therapeutics Announces Multi-Target Drug Discovery Collaboration Agreement with Zentalis PharmaceuticalsPresentation Format:  12:00 p.m. to 1:30 p.m. – Presentation and Lunch Contact: Raymond Oliver CEO, Bear Creek Capital 321-439-2120 [email protected]